Dr. Peter H. Win, MD
Ophthalmology (Ophthalmology Physician)
234 S 1st Ave Ste 101
Arcadia, CA 91006
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,435
Licensed in California since 2003, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A85277 (first issued 2003; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Pih Health Hospital-Whittier Whittier, CA
Medical groups
- Alliance Eye Medical Group Inc (4 clinicians)
- Peter Ho Win MD Inc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,435
- Services billed
- 13,571
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Imaging of retina | 2,532 | 933 |
| Injection of drug into eye | 1,515 | 292 |
| Established patient problem focused exam of visual system | 1,378 | 415 |
| Compounded drug, not otherwise classified | 1,216 | 253 |
| Extended exam of the back part of the eye with retinal drawing | 1,119 | 681 |
| Established patient office or other outpatient visit, 20-29 minutes | 723 | 220 |
| Established patient complete exam of visual system | 662 | 482 |
| Photography of the retina | 617 | 506 |
| Injection, aflibercept, 1 mg | 456 | 33 |
| Established patient office or other outpatient visit, 30-39 minutes | 304 | 240 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cyclosporine Other prescribers in Arcadia, CA | 495 |
| Ketorolac Tromethamine Other prescribers in Arcadia, CA | 412 |
| Latanoprost Other prescribers in Arcadia, CA | 376 |
| Restasis (cyclosporine) Other prescribers in Arcadia, CA | 371 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Arcadia, CA | 236 |
| Brimonidine Tartrate Other prescribers in Arcadia, CA | 210 |
| Prednisolone Acetate Other prescribers in Arcadia, CA | 196 |
| Timolol Maleate Other prescribers in Arcadia, CA | 195 |
| Azelastine Hcl Other prescribers in Arcadia, CA | 189 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Arcadia, CA | 189 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $397 in total to this clinician.
| Sun Pharmaceutical Industries Inc. | $115 |
|---|---|
| Harrow Eye, LLC | $105 |
| Alcon Vision LLC | $102 |
| Astellas Pharma US Inc | $31.45 |
| Bausch & Lomb Americas Inc. | $25.00 |
| Biomerieux Inc | $19.00 |
| Food and Beverage | $397 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $1,018,713 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
Kyowa Kirin, Inc. - A phase 2, multicenter, randomized, double-masked, parallel group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related m…
Kyowa Kirin, Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.